A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury

Inclusion Criteria: * Outpatient or inpatient subjects with a clinical diagnosis of OA or RA or any bone pain * Subjects expected to require regular anti-inflammatory therapy for arthritis symptom management * Subjects should have no history of peptic ulcer complications * Screening tests are negative for H pylori * Subjects who test positive can be re-screened after eradication of H. pylori Exclusion Criteria: * History of gastrointestinal (GI) hemorrhage * History of gastric or duodenal surgery * Presence of erosive esophagitis, gastric-outlet obstruction * Likelihood of requiring treatment during the study with drugs not permitted by the protocol * Impaired hepatic function (SGPT (ALT) or serum glutamate oxaloacetate transaminase (SGOT) (AST) \> 2 x upper limit of normal) or renal function (serum creatinine \> 200 umol/l) * Any other condition or baseline finding which, in the investigator's judgment, might increase risk to the subject or decrease the chance of obtaining satisfactory data to achieve study objectives * Anemia with Hb \< 10 g/dL * Suspected or clinical diagnosis of inflammatory bowel disease * Congestive heart failure (NYHA class III- IV) * Subjects considered to have a requirement for continued use of: * Corticosteroids (dose equivalent of prednisolone/ prednisone \>10mg daily stable dose) * disease-modifying antirheumatic drug (DMARDs) (unless stable dose for ≥ 12 weeks) * Iron replacement therapy (a dose \> 15mg elemental iron/day) * Iron replacement therapy (a dose \> 15mg elemental iron/day) or supplements for deficiency prevention (a dose ≤ 15mg elemental iron/day) due to anemia or any other reason * Double anti-platelet therapy (e.g. aspirin + Plavix) * Anti-coagulants * Anti-ulcer medications, e.g. sucralfate, H2 receptor antagonists (H2RAs), misoprostol, PPIs other than study medications * Sucralfate, misoprostol or regular H2 receptor antagonists (H2RAs) (\> 3 days/week) * COX-2 inhibitors * anti-ulcer medications or COX-2 selective inhibitor at screening allowed if treatments discontinued at this time